Immunovant Inc (IMVT)vsModerna Inc (MRNA)
IMVT
Immunovant Inc
$37.29
+0.30%
HEALTHCARE · Cap: $7.68B
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
IMVT leads profitability with a 0.0% profit margin vs -141.4%. IMVT earns a higher WallStSmart Score of 23/100 (F).
IMVT
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMVT.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.4x book value
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMVT
IMVT has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IMVT
The primary concerns for IMVT are Price/Book, Revenue Growth, EPS Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IMVT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IMVT generates stronger free cash flow (-124M), providing more financial flexibility.
Bottom Line
IMVT scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immunovant Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?